SCHEMBL1176575

SCHEMBL1176575

CC(C)(C)NC(=O)c1ccc([NH])cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
HTT P42858 1/20 0.50
MAPT P10636 2/20 0.45
SIRT2 Q8IXJ6 1/20 0.45
CYP2C9 P11712 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
EPHX1 P07099 1/20 0.44
PRKAB2 O43741 1/20 0.44
PRKAG1 P54619 1/20 0.44
PRKAA2 P54646 1/20 0.44
PRKAA1 Q13131 1/20 0.44
PRKAG3 Q9UGI9 1/20 0.44
PRKAG2 Q9UGJ0 1/20 0.44
PRKAB1 Q9Y478 1/20 0.44
POLB P06746 1/20 0.44
HDAC1 Q13547 1/20 0.44
AOC3 Q16853 2/20 0.43
JAK2 O60674 1/20 0.43
MAOB P27338 1/20 0.43
RIPK1 Q13546 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17865779 0.89 LMNA (0.58) LMNAHTTMAPTSIRT2CYP2C9
SCHEMBL10577753 0.83 LMNA (0.50) LMNAHTTMAPTSIRT2CYP2C9
SCHEMBL2522600 0.83 LMNA (0.53) LMNAHTTMAPTSIRT2CYP2C9
SCHEMBL13762029 0.81 HDAC1 (0.67) LMNAHTTMAPTSMN1; SMN2POLB
SCHEMBL3716265 0.81 SRD5A2 (0.53) LMNAHTTCYP2C9SMN1; SMN2EPHX1
SCHEMBL25753418 0.81 LMNA (0.51) LMNAHTTMAPTSIRT2CYP2C9
SCHEMBL162828 0.81 TSHR (0.54) LMNAHTTMAPTSIRT2CYP2C9
SCHEMBL13701770 0.81 HDAC2 (0.59) LMNAHTTMAPTSMN1; SMN2EPHX1
SCHEMBL2264435 0.81 ALDH1A1 (0.61) LMNAHTTMAPTSMN1; SMN2HDAC1
SCHEMBL691761 0.79 KMT2A (0.56) LMNAHTTCYP2C9POLBHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110045397-A1 CHARGE CONTROL AGENT AND RELATED ART KURODA KAZUYOSHI 2011-02-24 US disclosed
US-20090053641-A1 CHARGE CONTROL AGENT AND RELATED ART ORIENT CHEMICAL INDUSTRIES, LTD. (JP) 2009-02-26 US disclosed
EP-1862860-A1 CHARGE CONTROL AGENT AND RELATED TECHNIQUE Orient Chemical Industries, Ltd. (JP) 2007-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090053641-A1 CHARGE CONTROL AGENT AND RELATED ART H1-4, CECR2, DOT1L LMNA 733/4885HTT 755/4885MAPT 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.